[1]郑 灵,郑庆伟,温江妹.同期放化疗治疗局限期小细胞肺癌患者放疗分割模式比较分析[J].福建医药杂志,2021,43(02):24-27.
　ZHENG Ling,ZHENG Qingwei,WEN Jiangmei.Comparison of hyperfractionation and conventional fractionation with concurrent chemoradiotherapy for limited-stage small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2021,43(02):24-27.
点击复制

同期放化疗治疗局限期小细胞肺癌患者放疗分割模式比较分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期数:
2021年02期
页码:
24-27
栏目:
临床研究
出版日期:
2021-04-15

文章信息/Info

Title:
Comparison of hyperfractionation and conventional fractionation with concurrent chemoradiotherapy for limited-stage small cell lung cancer
文章编号:
1002-2600(2021)02-0024-04
作者:
郑 灵; 郑庆伟; 温江妹
福建省龙岩市第二医院放疗科(龙岩 364000)
Author(s):
ZHENG Ling;  ZHENG Qingwei;  WEN Jiangmei
Department of Radiotherapy,the Second Hospital of Longyan,Longyan,Fujian 364000,China
关键词:
局限期小细胞肺癌;  超分割放疗;  化疗
Keywords:
limited-stage small cell lung cancer;  hyperfractionated radiotherapy;  chemotherapy
分类号:
R734.2
文献标志码:
B
摘要:
目的 观察同期放化疗治疗局限期小细胞肺癌放疗分割模式选择的临床效果。方法 将96例局限期小细胞肺癌患者,随机分成两组,化疗联合同期超分割组(1.5 Gy/次,2次/d,总剂量45 Gy)46例,化疗联合同期常规分割组(2 Gy/次,1次/d,总剂量60～66 Gy)50例。化疗方案为依托泊苷联合顺铂(EP)方案,1～2周期后介入放疗,放疗采用累及野的三维适形调强放疗,两组治疗后达完全缓解(CR)或近CR者序贯行脑预防性照射。比较两组患者的近期临床疗效、不良反应和近期生存率。结果 化疗联合同期超分割组和化疗联合同期常规分割组的局部控制率分别为82.61%和78%,1、2、3年的生存率分别为84.78%、60.87%、36.96%和72.00%、54.00%、34.00%,差异无统计学意义(P>0.05); 而放射性食道炎分别为32.61%和32.00%,差异无统计学意义(P>0.05); 放射性肺炎为17.39%和36.00%,差异有统计学意义(P<0.05); 骨髓抑制主要表现在粒细胞减少,胃肠反应主要表现在恶心、呕吐,两组发生率均比较高,差异无统计学意义(P>0.05)。结论 化疗联合同期超分割放疗与常规分割放疗治疗局限期小细胞肺癌临床疗效相当,不良反应患者能耐受,在临床上均可行。
Abstract:
Objective To observe the clinical effect of simultaneous radiotherapy and chemotherapy in the treatment of limited-stage small cell lung cancer.Methods Nighty-six patients with localized small cell lung cancer were randomly divided into two groups: chemotherapy combined with hyperfractionation group(1.5 Gy/twice a day, total dose 45 Gy)46 cases,and chemotherapy combined with conventional fractionation group(2 Gy/ once a day, total dose 60-66 Gy)50 cases.The chemotherapy regimen was EP regimen.After 1-2 cycles, interventional radiotherapy was used, and the radiotherapy was treated with three-dimensional conformal intensity modulated radiotherapy involving the field.The patients in the two groups who reached CR or near CR after treatment were treated with prophylactic brain irradiation.The short-term clinical efficacy, adverse reactions and short-term survival rate were compared between the two groups.Results The local control rates of chemotherapy combined with hyperfractionation group and chemotherapy combined with conventional fractionation group were 82.61% and 78%, respectively.The 1,2 and 3 year survival rates were 84.78%, 60.87%,and 36.96%, respectively, and 72.00%, 54.00% and 34.00%, respectively.The difference was not statistically significant(P>0.05).The incidence of radiation esophagitis was 32.61% and 32.00% respectively, and the difference was not statistically significant(P>0.05).Radiation pneumonia was 17.39% and 36.00%, respectively.The difference was statistically significant(P<0.05).The main manifestation of myelosuppression is neutropenia.Gastrointestinal reactions were mainly now nausea and vomiting, the incidence of the two groups was relatively high, the difference was not statistically significant(P>0.05). Conclusion The clinical efficacy of chemotherapy combined with hyperfractionated radiotherapy and conventional fractionated radiotherapy is similar to that of conventional fractionated radiotherapy in the treatment of limited-stage small cell lung cancer.The adverse reaction can be tolerated by the patients.Both methods are clinically feasible.

参考文献/References:

[1] 尤静,于会明,宋马小薇,等.局限期小细胞肺癌加速超分割放疗同步EP方案化疗的剂量递增I期研究[J].中国肺癌杂志,2017,20(1):55-60.
[2] 王伟力,钟文,刘大伟,等.胸部放疗分割与局限期小细胞肺癌失败模式的相关性研究[J].现代肿瘤医学,2017,25(2):216-219.
[3] Rodriguez de Dios N,Calvo P,Rico M, et al.Recent developments in radiotherapy for small-cell lung cancer:a review by the oncologic group for the Study of lung cancer(Spanish radiation oncology society)[J].Clin Transl Oncol,2017,19(10):1183-1192.
[4] Noda K,Nishiwaki Y,Kawahara M,et al.Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J].N Engl J Med,2002,346(2):85-91.
[5] 殷蔚伯, 谷铣之.肿瘤放射治疗学[M].3版.北京:中国协和医科大学出版社, 2002: 1108-1111.
[6] 殷蔚伯,余子豪,徐国镇,等.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:601-608.
[7] Waqar S N,Mrgensztemn D.Treatment advanoes in small cell lung cancer(SCLC)[J]. Pharmacol Ther, 2017, 180: 16-23.
[8] De D,Pijls Johannesma M,Bentzen S M,et al.Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].J Clin Oncol, 2006, 24(7): 1057-1063.
[9] 蓝柳.局限期小细胞肺癌的胸部放射治疗进展[J].癌症进展,2010,5(8):232.
[10] Censheimer M F,Loo B W.Optimal radiation therapy for smallcell lung cancer[J].Curr yreat Options Onod,2017,18(21):1-9.
[11] Kalemkerian G P.Small cell lung cancer[J].Semin Respir Crit C are Med, 2016,37(5):783-796.
[12] Faivre-Finn C,Snee M,Ashcroft L,et al.Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer(CONVERT):an open-label,phase3,randomised,superiority trial[J].Lancet Oncol, 2017, 18(8): 1116-1125.
[13] Zhu L,Zhang S,Xu X,et al.Increased biological effective dose of radiation correlates with prolonged survival of patients with limited-stage small cell lung cancer:a systematic review[J].PLoS One, 2016, 11(5): e0156494.
[14] 刘亚洲,徐海亭,李文广.同步放化疗治疗局限期小细胞肺癌疗效分析[J].癌症进展,2007,5(3):393.

更新日期/Last Update: 2021-04-15